Cargando…
Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
BACKGROUND: A rapid increase in bone turnover and bone loss has been observed in response to the discontinuation of denosumab. It led to an acute increase in the fracture risk, similar to that observed in the untreated patients. We aimed to investigate the effect of denosumab on osteoclast (OC) prec...
Autores principales: | Kong, Sung Hye, Kim, Jung Hee, Kim, Sang Wan, Jeong, Ae Jin, Lee, Song-Hee, Ye, Sang-Kyu, Shin, Chan Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Bone and Mineral Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208900/ https://www.ncbi.nlm.nih.gov/pubmed/35718926 http://dx.doi.org/10.11005/jbm.2022.29.2.93 |
Ejemplares similares
-
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016) -
Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021) -
Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022) -
Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
por: Kang, Taewook, et al.
Publicado: (2022) -
Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study
por: Spangler, Leslie, et al.
Publicado: (2023)